Efficacy of dupilumab in prurigo nodularis in elderly patient.
dupilumab
elderly patient
prurigo nodularis
prurigo nodularis therapy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
26
10
2019
accepted:
17
12
2019
pubmed:
20
12
2019
medline:
25
11
2020
entrez:
20
12
2019
Statut:
ppublish
Résumé
Prurigo nodularis (PN) is a chronic disorder, affecting adults, with multiple nodules, typically on the limbs. The treatment is challenging, especially in elderly patients. An 85-year-old woman had developed in the last 3 years itch with nodular lesions and erythematous scaly patches and excoriations. The extension of the lesions was evaluated by body surface area (BSA) score and the patient's itch and disease-related sleep disorders by a Numeric Rating Scale (NRS) from 0 to 10. The Dermatology Life Quality Index (DLQI) and blood chemistry were performed before and during the therapy. At the baseline, the BSA score was 56%. Itch and disease-related sleep disorders were, respectively, NRS 10 and 5 and DLQI was 9. Total IgE count and lactate dehydrogenase were increased. After starting dupilumab, there was a rapid improvement, especially in pruritus. The patient reported the maximum peak of pruritus every day for 6 months. At this time, the itch almost disappeared and clinically only postinflammatory lesions appreciated, with normalization of the blood tests and without any side effects.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13201Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Beck, K. M., Yang, E. J., Sekhon, S., Bhutani, T., & Liao, W. (2019). Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatology, 155, 118-120.
Calugareanu A, Jachiet M, Tauber M, Nosbaum A, Aubin F, Misery L, Droitcourt C, Barbarot S, Debarbieux S, Saussine A, Bagot M, de Masson A, Sénéschal J, Staumont-Sallé, Bouaziz JD; Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. French Group of Research and Study in Atopic Dermatitis (Groupe de Recherche sur l'Eczéma Atopique, GREAT) from the French Society of Dermatology (SFD). Journal of the European Academy of Dermatology and Venereology 2019 Sep 17. https://doi.org/10.1111/jdv.15957
Ferrucci, S., Tavecchio, S., Berti, E., & Angileri, L. (2019 Sep). Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: Our experience of efficacy. The Journal of Dermatological Treatment, 2, 1-2.
Fukushi, S., Yamasaki, K., Aiba, S. (2011). Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. The British Journal of Dermatology, 165(5), 990-996.
Mollanazar, N. K., Elgash, M., Weaver, L., Valdes-Rodriguez, R., & Hsu, S. (2019). Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatology, 155(1), 121-122.
Napolitano, M., Fabbrocini, G., Scalvenzi, M., Nisticò, S. P., Dastoli, S., & Patruno, C. (2019 Sep). Effectiveness of dupilumab for the treatment of generalized prurigo nodularis clinical phenotype of adult atopic dermatitis. Dermatitis, 11. https://doi.org/10.1097/DER.0000000000000517
Rambhia, P.H., & Levitt, J.O. (2019). Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Reports, 5(5), 471-473.
Tanis, R., Ferenczi, K., & Payette, M. (2019 Sep 1). Dupilumab treatment for prurigo nodularis and pruritis. Journal of Drugs in Dermatology, 18(9), 940-942.
Zeidler, C., Tsianakas, A., Pereira, M., Ständer, H., Yosipovitch, G., & Ständer, S. (2018). Chronic prurigo of nodular type: A review. Acta Dermato-Venereologica, 98, 173-179.
Zhai, L. L., Savage, K. T., Qiu, C. C., Jin, A., Valdes-Rodriguez, R., & Mollanazar, N. K. (2019). Chronic pruritus responding to dupilumab-A case series. Medicines (Basel), 6(3). https://doi.org/10.3390/medicines6030072